Refine by
Based Vaccine Suppliers Serving Ireland
22 companies found
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
based inO Porriño, Pontevedra, SPAIN
In CZ Vaccines we develop and manufacture an extensive range of vaccines and biological products for multinational companies, laboratories and governments around the world. CZ Vaccines belongs to Zendal, a biopharmaceutical group that draws together ...
based inAbingdon, UNITED KINGDOM
Thermally Stable Needle Free Solid Dose Vaccines. Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies. These diseases affect millions of ...
based inAuburn, ALASKA (USA)
SiO2 Materials Science is focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. In the pharma segment, we solve more than 30 problems including some of the most challenging related to drug stability, drug ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Complementary Research & Development areas of expertise in immunology. Accelerating target identification, product validation and beyond. Delivering first-in-class therapies activating and regulating the immune ...
based inSan Carlos, CALIFORNIA (USA)
Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at scale. We do this by re-engineering how highly complex ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inUppsala, SWEDEN
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane ...
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune ...
based inPhiladelphia, PENNSYLVANIA (USA)
With extensive experience optimising processes for analytical, production and R&D laboratories across multiple industries and regulatory environments, we provide consistent, quality informatics solutions. We operate on a truly global basis, serving ...
To support the manufacturing of Cell and Gene Therapies, we have developed innovative chromatography solutions, specifically designed to improve the downstream purification of mRNA and viral vectors such as the Adeno-Associated Virus (AAV), ...
based inHangzhou City, CHINA
Cnpair Biotech Co., Ltd. is a professional provider which concentrates on IVD core materials, including antibodies and proteins, and we are dedicated to developing and delivering highly competitive antibodies and proteins with outstanding ...
based inSt-Jean, QUEBEC (CANADA)
We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for ...
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The ...
based inSchlieren, SWITZERLAND
Virometix is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer. Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a ...
Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. Emergence of new bacterial ...
based inWoburn, MASSACHUSETTS (USA)
We are an investigational-stage infectious disease company focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections. Using our proprietary technology, we are developing rationally ...
One of the most celebrated achievements of modern medicine is the eradication of the smallpox virus with the use of a live-attenuated vaccine. We are advancing the applied science of attenuating live viruses to develop an entirely ...
based inBerlin, GERMANY
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We ...
All our proprietary cell lines are characterized by excellent productivity, safety, and stability. They are used in the industrial production of virus-based vaccines or recombinant proteins and are suitable for the ...
based inAmes, ALABAMA (USA)
Mazen Animal Health harnesses the power of plant biotechnology to create orally delivered biologics, aimed at significantly improving animal health and welfare. The company's innovative cross-species platform is versatile enough to target various ...
based inScotland, UNITED KINGDOM
Aqualife is a global leader in fish care and vaccination services. We work with clients around the world to deliver a range of professional services to the aquaculture industry, working in partnership with our clients to ensure their fish are well ...
based inOxford, UNITED KINGDOM
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease ...
Recombinant Chikungunya Virus-Like Particles produced in mammalian HEK293 cells. Chikungunya structural proteins are transiently expressed to form a particle comprising E1, E2 and capsid protein, without the non-structural proteins or genome. ...
based inShirley, NEW YORK (USA)
CD BioSciences, a New York-based company, is currently developing a silicon-based high throughput DNA synthesis method. Our htDNA-chip technology platform makes it possible to synthesize DNA with high throughput, efficiency and precision. It expands ...
The nucleic acid vaccines development process is mainly divided into the following steps: isolation and screening of pathogenic genes, sequencing of pathogenic genes, targeted cloning of antigen genes, the introduction of recombinant genes into ...
based inDallas, TEXAS (USA)
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology ...
Employs a “multitope” approach to neutralizing the SARS-CoV-2 virus, eliciting a well-balanced B and T-cell response against multiple viral epitopes. Phase 1 and Phase 2 trials of UB-612 have shown UB-612 to be well tolerated, with no ...